INVESTIGATIONAL PIPELINE

A POWERFUL RESEARCH AND DEVELOPMENT ENGINE

PIPELINE & MEDICINES

INVESTIGATIONAL PIPELINE

Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.

Explore the Regeneron clinical pipeline

Select therapeutic area(s):
Select phase(s):
Select collaborator(s):

Displaying item

Clear Filters

Phase 1

  • ALN-APP5
    APP RNAi Therapeutic Early-onset Alzheimer’s disease
  • ALN-HSD5
    HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis
  • FIANLIMAB
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
  • NTLA-20014
    CRISPR/Cas9 Transthyretin amyloidosis
  • ODRONEXTAMAB
    CD20 X CD3 Antibody Certain B-cell malignancies
  • REGN4018
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
  • REGN4336
    PSMA X CD3 Prostate cancer
  • REGN5093
    MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
  • REGN5093-M114
    MET X MET Antibody MET overexpressing advanced cancer
  • REGN5381/REGN9035
    Agonist Antibody to NPR1/Reversal Agent to REGN5381 Heart failure
  • REGN5459
    BCMA X CD3 Antibody Transplant desensitization in patients with chronic kidney disease
  • REGN5668
    MUC16 x CD28 Platinum-resistant ovarian cancer
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
  • REGN6569
    GITR Antibody Solid tumors
  • REGN7257
    IL-2Rg Antibody Aplastic anemia
  • REGN7075
    EGFR x CD28 Solid tumors
  • REGN9933
    Factor XI Antibody Thrombosis
  • Next Generation Covid-19 Antibodies
    Antibodies to SARS-CoV-2 Variants Healthy volunteers

Phase 2

  • CEMIPLIMAB1
    PD-1 Antibody Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC, second-line cervical cancer ISA101b combination
  • CEMDISIRAN5
    C5 siRNA Therapeutic Immunoglobulin A nephropathy
  • DUPILUMAB1
    IL-4R Antibody Peanut allergy, grass allergy
  • EVINACUMAB7
    ANGPTL-3 Antibody Acute pancreatitis prevention
  • GARETOSMAB
    Activin-A Antibody Fibrodysplasia ossificans progressiva (FOP)
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
  • POZELIMAB
    C5 Antibody CD55-deficient protein-losing enteropathy
  • REGN4461
    LEPR Agonist Antibody Generalized lipodystrophy, partial lipodystrophy
  • REGN5458
    BCMA X CD3 Antibody Multiple myeloma
  • SARILUMAB1
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

Phase 3

  • AFLIBERCEPT 8MG3
    VEGF-Trap Wet age-related macular degeneration (AMD), diabetic macular edema (DME)
  • AFLIBERCEPT3
    VEGF-Trap Retinopathy of prematurity (ROP)
  • ALIROCUMAB
    PCSK9 Antibody Heterozygous familial hypercholesterolemia (HeFH) in pediatrics
  • CASIRIVIMAB AND IMDEVIMAB6
    SARS-CoV-2 Virus Multi-Antibody Therapy COVID-19 treatment in hospitalized patients, COVID-19 prevention
  • CEMIPLIMAB1
    PD-1 Antibody First-line non-small cell lung cancer (NSCLC) chemo combination, second-line cervical cancer, adjuvant CSCC
  • DUPILUMAB1
    IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–5 y.o; eosinophilic esophagitis (EoE) in adults, adolescents, and pediatrics; chronic obstructive pulmonary disease (COPD); bullous pemphigoid; prurigo nodularis; chronic spontaneous urticaria; allergic bronchopulmonary aspergillosis; chronic inducible urticaria - cold; chronic sinusitis without nasal polyposis; allergic fungal rhinosinusitis; chronic pruritis of unknown origin
  • FASINUMAB2
    NGF Antibody Osteoarthritis pain of the knee or hip
  • FIANLIMAB
    LAG-3 Antibody first-line metastatic melanoma
  • ITEPEKIMAB1
    IL-33 Antibody Chronic obstructive pulmonary disease (COPD)
  • POZELIMAB + CEMDISIRAN5
    C5 Antibody + C5 siRNA Therapeutic Paroxysmal nocturnal hemoglobinuria, myasthenia gravis
  • REGN1908-1909
    Fel d 1 Multi-Antibody Therapy Cat allergy
  • REGN5713-5714-5715
    Bet v 1 Multi-Antibody Therapy Birch allergy

No results found. Please adjust your filter selection and try again.

1Sanofi

2Teva and Mitsubishi Tanabe

3Bayer

4Intellia

5Alnylam

6Roche

7In collaboration with Ultragenyx outside of the U.S.

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Scientific trailblazers

Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.

Our Current Research

Discover our clinical trials

Learn more about our clinical trials and find one near you.

Find Trials

Back to top